2 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 2 |
Follow Lethargy: new trials by email Literature Review of Lethargy trials Research Report on Lethargy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. Lumateperone 42 mg, Risperidone 2 mg - Apathy, Schizophrenia | Phase 3 | Recruiting | Louisiana State University Health Sciences Center Shreveport | 80 | 2024-06-01 | 2024-07-01 |
| In Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. Positron Emission Tomography (PET) with [18F]-FDOPA, Positron Emission Tomography (PET) with [18F]-FEOBV, Magnetic Resonnance Imaging (MRI) - Apathy | Phase 3 | Recruiting | University Hospital, Bordeaux | 30 | 2021-04-13 | 2026-06-10 |
Mental Disorders (1) · Psychotic Disorders (1) · Schizophrenia (1) · Stroke (1)
Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Vascular Diseases (1)
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Aripiprazole (1) · Magnetic Resonance Spectroscopy (1) · Olanzapine (1) · Quetiapine Fumarate (1) · Risperidone (1) · fluorodopa F 18 (1) · lumateperone (1) · ziprasidone (1)
Louisiana State University Health Sciences Center Shreveport (1) · University Hospital, Bordeaux (1)
France (1) · United States (1)
Shawn McNeil, MD (1)